Targeting isoforms of RON kinase (MST1R) drives antitumor efficacy-Reference-Cited by-同舟云学术

Targeting isoforms of RON kinase (MST1R) drives antitumor efficacy

Published:2023-11-06 Issue:12 Volume:30 Page:2491-2507
ISSN:1350-9047
Container-title:Cell Death & Differentiation
language:en
Short-container-title:Cell Death Differ

Author:

Kim Joseph,Koh Dong-In,Lee Minki,Park Yoon Sun,Hong Seung-Woo,Shin Jae-Sik,Lee Mi So,Kim Min-Hwa,Lee Jun Hyung^ORCID,Jeong Joonyee,Bae Seunggeon,Hong Jun Ki,Jeong Hong-Rae,Ryu Yea Seong,Kim Seung-Mi,Choi Mingee^ORCID,Kim Hyojin,Ryu Hyun,Hur Sun-Chul,Park Junho^ORCID,Hur Dae Young,Jin Dong-Hoon^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

https://www.nature.com/articles/s41418-023-01235-9.pdf

Reference51 articles.

1. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14:101174.

2. Misale S, Nicolantonio FD, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014;4:1269–80.

3. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med. 2011;154:37–19.

4. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–45.

5. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28:1254–61.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the secrets: Evolution of resistance mediated by membrane proteins;Drug Resistance Updates;2024-11